Vanadate Is a Potent Activator of Endothelial Nitric-Oxide Synthase: Evidence for the Role of the Serine/Threonine Kinase Akt and the 90-kDa Heat Shock Protein

Andreas Papapetropoulos, David Fulton, Michelle I. Lin, Jason Fontana, Timothy J. McCabe, Stefan Zoellner, Guillermo García-Cardeña, Zongmin Zhou, Jean Phillipe Gratton, William C. Sessa

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We investigated the molecular mechanisms of sodium vanadate (vanadate)-induced nitric oxide (NO) production. Exposure of bovine lung microvascular cells (BLMVEC) to vanadate increased the release of biologically active NO in endothelium/smooth muscle cocultures, as measured by the accumulation of its surrogate marker, cGMP. This release was sensitive to NO synthase (NOS) inhibition and was greater than that observed with ionomycin. Although calcium chelators (BAPTA, EGTA) inhibited basal and ionomycin-induced NO production, they failed to inhibit vanadate-induced NO release. Moreover, in the absence of calcium/calmodulin, cell lysates from vanadate-treated cells exhibited greater NOS activity compared with control cells. Vanadate activates the phosphoinositide3-kinase (P13-K)/Akt pathway, which is known to increase endothelial NOS (eNOS) activity by direct phosphorylation of Ser-1179. Treatment of BLMVEC with vanadate resulted in phosphorylation of both Akt and endothelial NOS. In addition, wortmannin, a P13-K inhibitor, blocked both the vanadate-induced phosphorylation of eNOS and the increase in cGMP accumulation. Similarly, adenovirus-mediated gene transfer of an activation deficient form of Akt (AA-Akt) blocked the release of NO brought about by vanadate. To further investigate the mechanism of action of vanadate, eNOS was immunoprecipitated and its association with proteins that alter eNOS activity was tested. Immunoblots demonstrated that the eNOS-caveolin interaction remained unaffected by vanadate, whereas vanadate promoted recruitment of the 90-kDa heat shock protein (hsp90) to eNOS. We conclude that vanadate causes NO release via a mechanism that involves Akt-induced eNOS phosphorylation and increased binding of the activator protein hsp90 to eNOS.

Original languageEnglish (US)
Pages (from-to)407-415
Number of pages9
JournalMolecular pharmacology
Volume65
Issue number2
DOIs
StatePublished - Feb 1 2004
Externally publishedYes

Fingerprint

HSP90 Heat-Shock Proteins
Vanadates
Nitric Oxide Synthase Type III
Protein-Serine-Threonine Kinases
Nitric Oxide
Nitric Oxide Synthase
Phosphorylation
Ionomycin
Caveolins
Egtazic Acid
Calmodulin
Coculture Techniques
Adenoviridae
Transcriptional Activation
Endothelium
Smooth Muscle

ASJC Scopus subject areas

  • Pharmacology

Cite this

Vanadate Is a Potent Activator of Endothelial Nitric-Oxide Synthase : Evidence for the Role of the Serine/Threonine Kinase Akt and the 90-kDa Heat Shock Protein. / Papapetropoulos, Andreas; Fulton, David; Lin, Michelle I.; Fontana, Jason; McCabe, Timothy J.; Zoellner, Stefan; García-Cardeña, Guillermo; Zhou, Zongmin; Gratton, Jean Phillipe; Sessa, William C.

In: Molecular pharmacology, Vol. 65, No. 2, 01.02.2004, p. 407-415.

Research output: Contribution to journalArticle

Papapetropoulos, Andreas ; Fulton, David ; Lin, Michelle I. ; Fontana, Jason ; McCabe, Timothy J. ; Zoellner, Stefan ; García-Cardeña, Guillermo ; Zhou, Zongmin ; Gratton, Jean Phillipe ; Sessa, William C. / Vanadate Is a Potent Activator of Endothelial Nitric-Oxide Synthase : Evidence for the Role of the Serine/Threonine Kinase Akt and the 90-kDa Heat Shock Protein. In: Molecular pharmacology. 2004 ; Vol. 65, No. 2. pp. 407-415.
@article{836197ea5b2e4330bd7452c18d16d09c,
title = "Vanadate Is a Potent Activator of Endothelial Nitric-Oxide Synthase: Evidence for the Role of the Serine/Threonine Kinase Akt and the 90-kDa Heat Shock Protein",
abstract = "We investigated the molecular mechanisms of sodium vanadate (vanadate)-induced nitric oxide (NO) production. Exposure of bovine lung microvascular cells (BLMVEC) to vanadate increased the release of biologically active NO in endothelium/smooth muscle cocultures, as measured by the accumulation of its surrogate marker, cGMP. This release was sensitive to NO synthase (NOS) inhibition and was greater than that observed with ionomycin. Although calcium chelators (BAPTA, EGTA) inhibited basal and ionomycin-induced NO production, they failed to inhibit vanadate-induced NO release. Moreover, in the absence of calcium/calmodulin, cell lysates from vanadate-treated cells exhibited greater NOS activity compared with control cells. Vanadate activates the phosphoinositide3-kinase (P13-K)/Akt pathway, which is known to increase endothelial NOS (eNOS) activity by direct phosphorylation of Ser-1179. Treatment of BLMVEC with vanadate resulted in phosphorylation of both Akt and endothelial NOS. In addition, wortmannin, a P13-K inhibitor, blocked both the vanadate-induced phosphorylation of eNOS and the increase in cGMP accumulation. Similarly, adenovirus-mediated gene transfer of an activation deficient form of Akt (AA-Akt) blocked the release of NO brought about by vanadate. To further investigate the mechanism of action of vanadate, eNOS was immunoprecipitated and its association with proteins that alter eNOS activity was tested. Immunoblots demonstrated that the eNOS-caveolin interaction remained unaffected by vanadate, whereas vanadate promoted recruitment of the 90-kDa heat shock protein (hsp90) to eNOS. We conclude that vanadate causes NO release via a mechanism that involves Akt-induced eNOS phosphorylation and increased binding of the activator protein hsp90 to eNOS.",
author = "Andreas Papapetropoulos and David Fulton and Lin, {Michelle I.} and Jason Fontana and McCabe, {Timothy J.} and Stefan Zoellner and Guillermo Garc{\'i}a-Carde{\~n}a and Zongmin Zhou and Gratton, {Jean Phillipe} and Sessa, {William C.}",
year = "2004",
month = "2",
day = "1",
doi = "10.1124/mol.65.2.407",
language = "English (US)",
volume = "65",
pages = "407--415",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Vanadate Is a Potent Activator of Endothelial Nitric-Oxide Synthase

T2 - Evidence for the Role of the Serine/Threonine Kinase Akt and the 90-kDa Heat Shock Protein

AU - Papapetropoulos, Andreas

AU - Fulton, David

AU - Lin, Michelle I.

AU - Fontana, Jason

AU - McCabe, Timothy J.

AU - Zoellner, Stefan

AU - García-Cardeña, Guillermo

AU - Zhou, Zongmin

AU - Gratton, Jean Phillipe

AU - Sessa, William C.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - We investigated the molecular mechanisms of sodium vanadate (vanadate)-induced nitric oxide (NO) production. Exposure of bovine lung microvascular cells (BLMVEC) to vanadate increased the release of biologically active NO in endothelium/smooth muscle cocultures, as measured by the accumulation of its surrogate marker, cGMP. This release was sensitive to NO synthase (NOS) inhibition and was greater than that observed with ionomycin. Although calcium chelators (BAPTA, EGTA) inhibited basal and ionomycin-induced NO production, they failed to inhibit vanadate-induced NO release. Moreover, in the absence of calcium/calmodulin, cell lysates from vanadate-treated cells exhibited greater NOS activity compared with control cells. Vanadate activates the phosphoinositide3-kinase (P13-K)/Akt pathway, which is known to increase endothelial NOS (eNOS) activity by direct phosphorylation of Ser-1179. Treatment of BLMVEC with vanadate resulted in phosphorylation of both Akt and endothelial NOS. In addition, wortmannin, a P13-K inhibitor, blocked both the vanadate-induced phosphorylation of eNOS and the increase in cGMP accumulation. Similarly, adenovirus-mediated gene transfer of an activation deficient form of Akt (AA-Akt) blocked the release of NO brought about by vanadate. To further investigate the mechanism of action of vanadate, eNOS was immunoprecipitated and its association with proteins that alter eNOS activity was tested. Immunoblots demonstrated that the eNOS-caveolin interaction remained unaffected by vanadate, whereas vanadate promoted recruitment of the 90-kDa heat shock protein (hsp90) to eNOS. We conclude that vanadate causes NO release via a mechanism that involves Akt-induced eNOS phosphorylation and increased binding of the activator protein hsp90 to eNOS.

AB - We investigated the molecular mechanisms of sodium vanadate (vanadate)-induced nitric oxide (NO) production. Exposure of bovine lung microvascular cells (BLMVEC) to vanadate increased the release of biologically active NO in endothelium/smooth muscle cocultures, as measured by the accumulation of its surrogate marker, cGMP. This release was sensitive to NO synthase (NOS) inhibition and was greater than that observed with ionomycin. Although calcium chelators (BAPTA, EGTA) inhibited basal and ionomycin-induced NO production, they failed to inhibit vanadate-induced NO release. Moreover, in the absence of calcium/calmodulin, cell lysates from vanadate-treated cells exhibited greater NOS activity compared with control cells. Vanadate activates the phosphoinositide3-kinase (P13-K)/Akt pathway, which is known to increase endothelial NOS (eNOS) activity by direct phosphorylation of Ser-1179. Treatment of BLMVEC with vanadate resulted in phosphorylation of both Akt and endothelial NOS. In addition, wortmannin, a P13-K inhibitor, blocked both the vanadate-induced phosphorylation of eNOS and the increase in cGMP accumulation. Similarly, adenovirus-mediated gene transfer of an activation deficient form of Akt (AA-Akt) blocked the release of NO brought about by vanadate. To further investigate the mechanism of action of vanadate, eNOS was immunoprecipitated and its association with proteins that alter eNOS activity was tested. Immunoblots demonstrated that the eNOS-caveolin interaction remained unaffected by vanadate, whereas vanadate promoted recruitment of the 90-kDa heat shock protein (hsp90) to eNOS. We conclude that vanadate causes NO release via a mechanism that involves Akt-induced eNOS phosphorylation and increased binding of the activator protein hsp90 to eNOS.

UR - http://www.scopus.com/inward/record.url?scp=9144250172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144250172&partnerID=8YFLogxK

U2 - 10.1124/mol.65.2.407

DO - 10.1124/mol.65.2.407

M3 - Article

C2 - 14742683

AN - SCOPUS:9144250172

VL - 65

SP - 407

EP - 415

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -